Challenging the pace of change in healthcare: Prescient Therapeutics
“The fact of the matter is there are people walking around now who shouldn’t be...
“The fact of the matter is there are people walking around now who shouldn’t be...
Prescient Therapeutics Ltd (ASX:PTX)’s PTX-100 for the treatment of peripheral T-cell lymphomas (PTCL) has been...
Prescient Therapeutics Ltd (ASX:PTX) has been granted a US patent for its flagship OmniCAR portfolio entitled...
All the major banks have now lifted interest rates in line with the Reserve Bank...
Prescient Therapeutics Ltd (ASX:PTX)'s Steven Yatomi-Clarke outlines the company's oncology treatment vision in a new...
Prescient Therapeutics Ltd (ASX:PTX)'s Steven Yatomi-Clarke explains how the company is combatting the leading, global...
Prescient Therapeutics Ltd (ASX:PTX) has signed an agreement related to advancing a new research program with...
Prescient Therapeutics (ASX: PTX) CEO and Managing Director Steven Yatomi-Clarke joined Steve Darling from Proactive...
The company’s goal is to harness OmniCAR’s innate adaptability and control to develop novel cell...
To stay up to date with Prescient Therapeutics news and events, please register your details.